Originating from Africa, India, and the Middle East, frankincense oil has been found to have many medicinal benefits. Now, an enriched extract of the Somalian Frankincense herb Boswellia carteri has been shown to kill off bladder cancer cells. Research presented in the open access journal, BMC Complementary and Alternative Medicine, demonstrates that this herb has the potential for an alternative therapy for bladder cancer.
Bladder cancer is twice as common in males as it is in females. In the US, bladder cancer is the fourth most common type of cancer in men, whilst in the UK it is the seventh most common cause of death amongst males.
HK Lin and his team, from the University of Oklahoma Health Sciences Center and Oklahoma City VA Medical Center, set out to evaluate frankincense oil for its anti-tumour activity in bladder cancer cells. The authors investigated the effects of the oil in two different types of cells in culture: human bladder cancer cells and normal bladder cells. The team found that frankincense oil is able to discriminate between normal and cancerous bladder cells in culture, and specifically kill cancer cells.
Gene expression analyses were performed to determine how frankincense oil affects bladder cancer cell survival. The team found that the oil suppresses cancer cell growth by arresting cell cycle progression and induces bladder cancer cell death by activating multiple cell death pathways.
Dr Lin said, "Frankincense oil may represent an inexpensive alternative therapy for patients currently suffering from bladder cancer."
Notes to Editors
1. Frankincense oil derived from Boswellia carteri induces tumor cell specific cytotoxicity
Mark Barton Frank, Qing Yang, Jeanette Osban, Joseph T Azzarello, Marcia R Saban, Ricardo Saban, Richard A Ashley, Jan C Welter, Kar-Ming Fung and Hsueh-Kung Lin
BMC Complementary and Alternative Medicine (in press)
During embargo, article available here: http://www.biomedcentral.com/imedia/9378358372323491_article.pdf?random=433357
After the embargo, article available at journal website: http://www.biomedcentral.com/bmccomplementalternmed/
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at firstname.lastname@example.org on the day of publication
2. BMC Complementary and Alternative Medicine is an open access journal publishing original peer-reviewed research articles in interventions and resources that complement or replace conventional therapies, with a specific emphasis on research that explores the biological mechanisms of action, as well as their efficacy, safety, costs, patterns of use and/or implementation. BMC Complementary and Alternative Medicine (ISSN 1472-6882) is indexed/tracked/covered by PubMed, MEDLINE, CAS, Scopus, EMBASE, Cinahl and Google Scholar.
3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.